5/26/2015 - 11:54 AM EST - Valeant Pharmaceuticals International, Inc. : announced that the U.S. FDA's decision date, or PDUFA date, is tomorrow regarding Salix Pharmaceuticals' supplemental Biologics License Application (sBLA) for the use of Xifaxan (rifaximin) for the treatment of irritable bowel syndrome with diarrhea. Xifaxan, an antibiotic, is currently cleared for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adult patients. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.89 at $293.55.
